Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
4.630
+0.160 (3.58%)
Feb 4, 2025, 4:00 PM EST - Market closed
Relay Therapeutics Employees
Relay Therapeutics had 323 employees as of December 31, 2023. The number of employees decreased by 4 or -1.22% compared to the previous year.
Employees
323
Change (1Y)
-4
Growth (1Y)
-1.22%
Revenue / Employee
$30,978
Profits / Employee
-$1,068,728
Market Cap
774.98M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 323 | -4 | -1.22% |
Dec 31, 2022 | 327 | 82 | 33.47% |
Dec 31, 2021 | 245 | 86 | 54.09% |
Dec 31, 2020 | 159 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RLAY News
- 4 weeks ago - Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - GlobeNewsWire
- 2 months ago - Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewsWire
- 2 months ago - Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewsWire
- 3 months ago - Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - GlobeNewsWire
- 5 months ago - Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion - Seeking Alpha